Фосфорал

Quick links

Choose a section

Quick links to important sections

Advertisements

Фосфорал

Selected form

Advertisements
Advertisements

Overview of Фосфорал

Property Description
Active ingredient Fosfomycin (as trometamol salt)
Form Granules for oral solution
Pharmacological class Antibiotic (Phosphonic acid derivative)
Origin Synthetic
General Purpose Bacterial elimination (Bactericidal effect)

Defining Фосфорал: Active Ingredient and Pharmacological Class

Фосфорал is a medicinal product whose active ingredient is Fosfomycin, primarily used as a targeted antibiotic for combating bacterial infections. The drug is classified within the phosphonic acid derivative class, representing a unique antibacterial category. Its structure is synthetic, chemically manufactured, and its activity profile is well-documented and recognized in clinical settings. Unlike common antibiotic families, the action of Fosfomycin is distinct, helping it retain efficacy against certain organisms that may exhibit resistance to other agents.

Forms, Composition, and General Purpose

The medication is most commonly supplied for patient use as granules for oral solution, a solid preparation that must be dissolved in a liquid vehicle prior to oral administration. The active ingredient is typically formulated as Fosfomycin trometamol (or tromethamine), which acts as a prodrug to enhance the absorption of the active Fosfomycin component into the body. This formulation is often provided in a single-dose sachet, a presentation that distinguishes it from multi-day antibiotic regimens. The unique bactericidal effect of Fosfomycin works by irreversibly disrupting the early stages of bacterial cell wall synthesis. This action is fundamental to its general purpose of actively killing and eliminating susceptible bacterial populations, a mechanism that is clinically recognized for its reliable efficacy.

Regulatory References

  1. FDA Label
Advertisements

What side effects are possible with Фосфорал?

Possible Side Effects and Safety Information

The safety profile of Фосфорал (Fosfomycin) is officially documented according to standardized regulatory classifications that detail potential adverse reactions by frequency and physiological system. This information is derived from government health authorities and clinical studies.

Frequency-Classified Adverse Reactions

The most Common side effects reported in official labeling involve the gastrointestinal and nervous systems, and include diarrhoea, nausea, headache, dizziness, dyspepsia, and fatigue. Uncommon reactions may include vomiting, abdominal pain, rash, and urticaria.

System-Organ-Class Safety Summary

Adverse reactions are grouped by the system-organ class affected:

  • Gastrointestinal Disorders: Diarrhoea, nausea, dyspepsia, vomiting, abdominal pain.
  • Nervous System Disorders: Headache, dizziness.
  • Immune System Disorders: Hypersensitivity reactions.

Serious Adverse Reactions and Safety Constraints

Certain reactions are classified as serious and are included in the regulatory documentation, such as Anaphylactic Shock, Angioedema (severe swelling), and Antibiotic-Associated Colitis (including Pseudomembranous colitis).

Use is contraindicated in individuals with known hypersensitivity to Fosfomycin. The official labeling also notes that co-administration with metoclopramide may lead to lower drug concentrations, potentially affecting efficacy. As with other antibiotics, there is a risk of the overgrowth of non-susceptible organisms.

Population-Specific Safety Notes

The safety profile includes considerations for specific populations. Caution is advised for individuals with severe renal impairment (kidney function impairment) due to the drug’s primary route of elimination. The safety and effectiveness for treating uncomplicated urinary tract infections are not established for children under 12 years of age in some regulatory jurisdictions.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Фосфорал (Fosfomycin) based on documented clinical manifestations and regulator-mandated emergency actions. In the event of overdosage, patients must seek immediate medical attention and contact a regional Poison Control Centre or hospital emergency department, as stipulated by government labeling.

Documented Overdose Manifestations

Overexposure may present with specific sensory and neurological signs. Documented manifestations include impaired hearing, vestibular loss, and changes in taste perception, such as a metallic taste. While clinical experience with oral overdose is limited, severe outcomes, including hypotonia, somnolence, and severe electrolyte disturbances, are referenced from regulatory experience with the high-dose intravenous formulation.

Required Management and Monitoring

The official instructions for managing overdosage specify that treatment must be symptomatic and supportive. No specific antidote is explicitly documented in the official labeling. Regulatory guidance requires that the patient be monitored, particularly for plasma/serum electrolyte levels. Procedures such as rehydration are recommended to promote urinary elimination, and haemodialysis is recognized as an effective procedure for clearing Fosfomycin from the body. A specific regulatory note highlights that Fosfomycin accumulates in patients with renal failure, which is a critical consideration in overdose scenarios.

Advertisements

Therapeutic Uses of Фосфорал

What Фосфорал Treats: Main Uses and Benefits

Фосфорал (Fosfomycin) is an antibiotic used primarily to manage acute bacterial infections within the lower urinary tract and is relevant for easing symptoms related to inflammatory or irritative states. Its main therapeutic use is for acute, uncomplicated cystitis.

The medication is applied to address conditions presenting with acute episodes, including acute cystitis and uncomplicated lower urinary tract infections that are driven by susceptible bacteria. It also finds use in specific clinical scenarios, such as prophylactic use after certain urological procedures to reduce risk, and is applicable in situations involving certain bacterial strains that are challenging to manage.

It is used for managing conditions that present with symptoms such as dysuria (painful urination), frequent need to urinate (frequency), and the sudden, compelling urge to urinate (urgency). In therapeutic use, Фосфорал supports the management of symptoms related to physical discomfort and assists with maintaining functional stability. This assists with managing symptoms that create noticeable physiological strain.


Quick Fact: Relief for Acute Discomfort

Quick Fact: Relief for Acute Discomfort Фосфорал supports comfort during periods of heightened symptoms and helps ease the symptomatic burden associated with inflammatory or irritative states.

Regulatory References

  1. US Food and Drug Administration (FDA) label
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Фосфорал?

The eligibility for Фосфорал (Fosfomycin trometamol) is strictly defined by regulatory criteria, primarily restricting its use to a specific patient population for uncomplicated infections. This information is based exclusively on official government-approved labeling.


Official Eligibility and Restrictions

Eligibility Category Regulatory Statement
Approved Population Adult women and female adolescents over 12 years of age for acute, uncomplicated cystitis.
Pediatric Restriction Not recommended for children below 12 years as safety and efficacy have not been established.
Contraindications Patients with known hypersensitivity to the drug or severe renal insufficiency (creatinine clearance < 10 mL/min).
Organ Function Contraindicated in patients undergoing dialysis; no dose adjustment is necessary for hepatic impairment.
Pregnancy Status Use is permitted only if clearly necessary (single-dose use is permitted in lactation if clearly necessary).

Use is not indicated for male patients or for infections classified as complicated (e.g., pyelonephritis). Patients with specific hereditary metabolic disorders (e.g., fructose intolerance) should also not use this medicine due to excipients in the formulation.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Фосфорал (Fosfomycin) interaction patterns are officially documented and classified by regulatory authorities based on their pharmacokinetic or pharmacodynamic effects. The administration profile of Fosfomycin requires attention to certain co-administered medicinal products and substances, as detailed in the official prescribing information.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Agent Official Effect and Restriction
Exposure Modification Metoclopramide (or other prokinetics) Co-administration significantly lowers the serum concentrations and urinary excretion of Fosfomycin. This combination is generally avoided to maintain adequate exposure.
Pharmacodynamic Antagonism Live Bacterial Vaccines (e.g., BCG, Cholera) Antibiotic action may result in pharmacodynamic antagonism against the vaccine, potentially reducing its effectiveness.
Pharmacodynamic Risk Oral Anticoagulants Official labeling notes a risk of altered International Normalized Ratio (INR), a general class effect reported with antibiotic use, requiring close monitoring.

Administration Constraints and Clearance

Food intake is documented to reduce the rate and extent of oral absorption of Fosfomycin, resulting in a decreased maximum concentration (Cmax). For optimal pharmacokinetics, regulatory documents specify a timing preference to take the product on an empty stomach or separated by 2–3 hours from meals. Furthermore, renal impairment (creatinine clearance less than 54 mL/min) significantly decreases drug excretion, resulting in a prolonged half-life and increased systemic exposure in this population.

Advertisements

Mechanism of Action

Irreversible Blockade of Early Bacterial Cell Wall Synthesis

The primary mechanism involves the irreversible covalent inhibition of the bacterial enzyme UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), which is critical for initiating the production of the cell wall's essential precursor. By permanently halting this early step in cell wall biosynthesis, the drug causes the structural failure of the bacterial cell, resulting in cell lysis and death, which results in the bactericidal consequence of this mechanism.


️ Mechanistic Prerequisite: Bacterial Transporter Hijacking

For the mechanism to be effective, the active molecule must first gain entry into the bacterial cell's interior by exploiting native uptake systems, primarily the L-α-glycerophosphate transporter (GlpT) and the hexose-6-phosphate transporter (UhpT). This requirement defines a critical mechanistic limitation: if bacteria lose these specific transporters, the drug cannot reach its target, and the core inhibitory mechanism is functionally rendered inoperable.

Advertisements

Dosage and Administration Information

How to Use Фосфорал

Фосфорал (Fosfomycin trometamol) is an antibiotic administered exclusively via the oral route as a liquid solution. The medication is supplied as granules, typically containing the equivalent of 3 grams of the active component, and its use is guided by the specific course of treatment established for the medicinal product.

Standardized Dosing and Frequency

For the management of acute uncomplicated cystitis in female adolescents and adults, the standard regimen is a single, one-time dose of 3 grams. This short duration of therapy is not meant to be repeated for the same infection episode. In specific clinical scenarios, such as perioperative prophylaxis for certain urological procedures, a two-dose regimen may be applied, requiring a second 3-gram dose approximately 24 hours after the first.

Preparation and Administration Protocol

The proper administration of this medication involves specific preparation steps. The contents of the sachet must be fully dissolved in 3 to 4 ounces (about half a cup) of cold or room temperature water and consumed immediately after preparation. The granules must not be swallowed dry or dissolved in hot liquid. Prescribing standards regarding the timing of intake vary; some specifications indicate consumption on an empty stomach (2–3 hours before or after food), while others permit taking it with or without a meal.

Use Constraints and Limits

Administration rules define high-level constraints for patient groups. The single 3 g dose is established for patients 12 years of age and older. Furthermore, use of the oral formulation is not recommended in patients who have severely compromised kidney function, defined by a creatinine clearance (CrCL) below 10 mL/min.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Фосфорал

This overview describes the types of clinical studies conducted on Фосфорал (Fosfomycin), the outcomes they measured, and what remains uncertain in the research landscape, strictly based on official regulatory and scientific literature.


Evidence for Use in Uncomplicated Cystitis

The primary research base for Фосфорал was established through studies exploring its use in acute, uncomplicated lower urinary tract infections (cystitis). This research is built on Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews that compile data from many individual trials. These studies examined the single-dose Fosfomycin regimen against other antibiotics used for these conditions.

Researchers in these trials primarily monitored two key outcomes: clinical symptom resolution and microbiological eradication. Clinical resolution referred to the observed changes in outcomes related to physical discomfort, such as painful or frequent urination, over defined short-term intervals. Microbiological eradication involved measuring whether the causative bacteria were eliminated from the urine. Studies monitored outcomes over defined time intervals, typically within the first few days and up to one month.

Findings describe patterns observed in the studies related to symptom resolution that were measured against those of comparison treatments at short-term follow-up. However, reported outcomes for the complete microbiological eradication of bacteria showed patterns related to variability across the research base. The overall volume and consistency of this research base is described as having a High level of evidence for this primary indication.


Evidence for Use in Prophylaxis

Research has also explored the use of Фосфорал for infection prevention (prophylaxis) related to specific medical procedures, most notably in adult men undergoing a transrectal prostate biopsy. This evidence is derived from a combination of dedicated Clinical Trials and analyses of Observational Cohort Data.

In these studies, research examined outcomes related to the prevention of post-procedural complications. This included monitoring physiological strain or stress, such as the incidence of fever or infection, in the immediate time period surrounding the procedure and for up to 30 days afterward. Evidence suggests that the results apply only to the specific populations studied, and certainty remains low regarding the optimal administration protocols for consistent prophylactic use in this setting. The overall evidence level for this specific use is assessed as Moderate.


Evidence in Special Populations

Research examined how Фосфорал was evaluated in several special populations to determine specific patterns in these groups. Studies monitored data for the elderly population with uncomplicated UTIs. Research has also explored the use of Фосфорал for Asymptomatic Bacteriuria (ASB) in pregnant women. Research explored paediatric use in the past, but certain regulatory bodies have noted limitations in the evidence base, and long-term outcomes remain uncharacterized for these younger populations.


Durability of Response and Long-Term Follow-up

Most key clinical trials and regulatory reviews focus primarily on short-term outcomes related to physical discomfort and microbiological status. Follow-up durations were often limited to a period of approximately 5 to 30 days post-treatment. This means that research provides insight into short-term changes, but not necessarily the long-term patterns. There is limited information for long-term outcomes regarding the sustained absence of infection or the prevention of future infections beyond this initial one-month period.


Key Limitations and Research Gaps

The research base for Фосфорал is subject to specific limitations that guide ongoing research: Findings were mixed when focusing strictly on the eradication of bacteria, leading to some uncertainty regarding the consistency of results across all trials. Additionally, data for certain groups, particularly paediatric populations, remain insufficient to fully characterize use in those populations. Regulatory reviews of some meta-analyses suggest that the evidence quality varies across studies, with some older component trials carrying a risk of methodological concerns.

Key Studies & References

  1. MONUROL (Fosfomycin Tromethamine) Granules for Oral Solution FDA Labeling
  2. MONUROL (Fosfomycin Tromethamine) Granules for Oral Solution FDA Labeling (Pharmacology)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Фосфорал (FAQ)


Q: How quickly does Фосфорал typically start working after I take it?

Regulatory documents state that official information does not specify an exact time for the start of symptom relief. Regulatory documents note that the drug's active component typically achieves its maximum concentration in the urine within a few hours after administration. Clinical studies primarily track outcomes related to symptom resolution over defined short-term intervals.


Q: Is Фосфорал the same type of medicine as others used for similar conditions?

Фосфорал (Fosfomycin) is classified by regulatory agencies as a phosphonic acid derivative, which is a unique class of antibacterial medicine. Its method of action, which involves irreversibly blocking the early steps in bacterial cell wall production, is distinct from many other commonly used antibiotic classes.


Q: Does Фосфорал usually cause stomach issues?

Yes, according to official regulatory summaries of clinical trials, gastrointestinal effects are among the most commonly reported side effects. These common effects may include diarrhoea, nausea, vomiting, abdominal pain, and general indigestion (dyspepsia).


Q: Can pregnant or breastfeeding individuals take Фосфорал?

Official labeling states that use during pregnancy and lactation is permitted only if a healthcare provider determines it is clearly necessary. Low levels of the drug may be excreted into human milk. Any use in these populations is described as requiring guidance from a healthcare professional.


Q: Can Фосфорал affect how other prescription drugs work?

Official regulatory documents indicate that Фосфорал can affect the concentrations of certain co-administered drugs and vice-versa. For instance, combination with prokinetic agents, like Metoclopramide, may lower the amount of Фосфорал absorbed. If taking oral anticoagulants (blood thinners), official information notes the need for close monitoring of blood clotting markers (INR).


Q: What is the difference between how Фосфорал works and similar drugs?

The mechanism of action for Фосфорал is unique: it irreversibly blocks a critical enzyme called MurA in the bacterial cell. This action permanently stops the initial steps required for the bacteria to build their cell wall, which results in the structural failure and death of susceptible bacterial cells.


Q: Is it normal to feel a bit different when first starting Фосфорал?

Regulatory documents list several effects that are common during treatment and may result in a change in how a person feels. These commonly reported effects include headache, dizziness, and fatigue.


Q: What are the key themes found in research about Фосфорал's benefits?

Official summaries of clinical research focus primarily on two key outcomes, which inform the understanding of the drug's benefits. These themes are clinical symptom resolution (the physical improvement of symptoms) and microbiological eradication (the elimination of the causative bacteria from the infection site).


Q: What happens if I miss a time to take Фосфорал?

The single-dose regimen is the established use for the main indication. For this or the official two-dose regimen (used in prophylaxis), official documents do not provide specific management instructions for a missed dose. All dosing decisions should be confirmed with the prescribing healthcare professional.


Q: Is it okay to drink alcohol while taking Фосфорал?

Official regulatory documents do not contain a specific statement or warning regarding a direct chemical interaction between Фосфорал and alcohol. However, official information suggests that alcohol consumption may potentially worsen some common side effects of the drug, such as headache, dizziness, or nausea.


Q: Does Фосфорал cause drowsiness or affect driving?

Official labeling notes that the medicine may cause effects such as dizziness or fatigue. Official information indicates that activities requiring mental alertness, such as driving or operating machinery, may be affected due to the potential for dizziness or fatigue.


Q: Are there specific food types that interact with Фосфорал?

Official documents state that food intake in general reduces the rate and total amount of Фосфорал absorbed into the body. Taking the product on an empty stomach is recommended to maximize absorption. No specific type of food (e.g., dairy or grapefruit) is identified as having a unique interaction beyond this general constraint.


Q: Does the time of day I take Фосфорал matter?

The most important administration requirement specified in official guidance is the timing relative to meals—that the dose be taken on an empty stomach (2–3 hours before or after eating) to ensure proper absorption. Official documents do not specify any other requirement regarding the absolute time of day (morning or evening) for the dose.


Q: Can Фосфорал be taken with caffeine-containing beverages?

Official preparation instructions specify dissolving the granules only in cold or room temperature water. While no direct chemical interaction with caffeine is listed, the preparation guidelines prioritize optimal absorption by specifying dissolution in water and administration on an empty stomach, rather than with other beverages.


Q: Why do some people need to take Фосфорал for a long time?

The approved use for the oral granules is primarily the single-dose regimen for uncomplicated cystitis. Official documents note a two-dose regimen for specific infection prevention (prophylaxis), but extended or long-term use is not an an officially supported regimen. Use beyond the officially approved durations for the oral formulation is not documented in the product label.


Q: Can Фосфорал impact fertility?

Studies on animals have not indicated any adverse effects on male or female fertility. According to official regulatory information, there is no evidence suggesting an adverse impact on human fertility.


Q: Does Фосфорал have any common effects on mood or sleep?

Official regulatory documents list side effects that affect the nervous system, such as headache and fatigue, which are common. However, specific changes in mood (like anxiety) or specific sleep disturbances (like insomnia) are not listed as common or serious adverse reactions.


Q: Is Фосфорал a controlled substance?

Фосфорал is classified as an antibiotic used to treat bacterial infections (a phosphonic acid derivative). The drug is not listed as a controlled substance under the regulatory scheduling systems of major government health authorities, such as the U.S. DEA.


Q: Is there public information on studies comparing Фосфорал to a placebo?

Official clinical trial summaries provided by regulatory bodies primarily describe studies that compared Фосфорал to other active antibiotics already on the market. While placebo-controlled trials are often foundational for drug approval, the evidence cited in labeling for the approved indication relies heavily on comparisons to established treatments.


Q: Does taking Фосфорал require any special monitoring by a doctor?

For the general patient population taking the single-dose regimen, routine monitoring is not officially required. However, official documents advise that patients who are concurrently taking oral anticoagulants must be closely monitored by a doctor for altered blood clotting markers (INR).

Advertisements

How should Фосфорал be stored and disposed of?

How to Store and Dispose of Фосфорал (Fosfomycin)

The official labeling for Фосфорал (Fosfomycin tromethamine) granules specifies precise conditions to maintain product stability and ensure safety.


Storage Requirements

Condition Requirement (Official Regulatory Statement)
Temperature Store at room temperature, typically defined as 15 C to 30 C (59 F to 86 F). Do not freeze.
Protection Keep the product in its original sachet container prior to mixing.
Child Safety Must be stored out of the sight and reach of children.

⏳ Stability After Mixing

The solution must be used immediately after the granules are dissolved in water. The labeling mandates immediate consumption due to the rapid decline in stability once the product is reconstituted.


️ Disposal Instructions

Official disposal guidance prioritizes the safe handling of unused or expired medicine. The best option is utilizing an authorized drug take-back location or mail-back program. If a take-back program is unavailable, non-hazardous product may be disposed of in household trash by mixing it with an undesirable substance (such as dirt or coffee grounds) and sealing the mixture in a bag or container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Фосфорал found in:

A-Z Index: